文献速递淋巴瘤造血干细胞移植与细胞治疗

Lisocabtagene maraleucel用于不适合造血干细胞移植的复发/难治性大B细胞淋巴瘤患者:2期PILOT研究最终结果

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.
PubMed 文献 · Blood Adv · 2025-01-01

PILOT研究最终分析纳入61例接受过1线治疗且符合至少1项不适合造血干细胞移植标准的复发/难治性大B细胞淋巴瘤成人患者,接受lisocabtagene maraleucel治疗。总缓解率为80%,完全缓解率54%;中位随访18.2个月,中位缓解持续时间23.3个月,中位无进展生存期9.0个月,中位总生存期未达到。作者认为结果支持lisocabtagene maraleucel作为该人群的二线治疗。

要点

  • 总缓解率80%,完全缓解率54%。
  • 中位缓解持续时间23.3个月,中位无进展生存期9.0个月。
  • 治疗期≥3级不良事件发生率79%,细胞因子释放综合征38%,神经系统事件31%。

核心结论

  • 在该高危特征人群中,lisocabtagene maraleucel显示出持久疗效和良好安全性,与既往报告一致。
  • 结果支持lisocabtagene maraleucel作为不适合造血干细胞移植的复发/难治性大B细胞淋巴瘤患者的二线治疗。

研究设计与样本

  • 2期PILOT研究最终分析,纳入61例接受过1线治疗且符合至少1项不适合造血干细胞移植标准的复发/难治性大B细胞淋巴瘤成人患者。
  • 主要终点为总缓解率;中位随访18.2个月。

主要发现

  • 总缓解率为80%,完全缓解率为54%。
  • 中位缓解持续时间为23.3个月(95%CI,6.2至未达到)。
  • 中位无进展生存期为9.0个月(95%CI,4.2至未达到),中位总生存期未达到(95%CI,16.3至未达到)。
  • 18个月无进展生存率和总生存率分别为43%(95%CI,30-55)和59%(95%CI,45-70)。
  • 治疗期(≤90天)≥3级不良事件发生率79%,细胞因子释放综合征38%(3级2%,无4/5级),神经系统事件31%(5级3%,无4/5级),≥3级感染7%。

关键数值与推荐

  • 总缓解率(主要终点)为80%,完全缓解率54%。
  • 中位缓解持续时间23.3个月(95%CI,6.2至未达到),中位无进展生存期9.0个月(95%CI,4.2至未达到)。
  • 18个月无进展生存率43%(95%CI,30-55),18个月总生存率59%(95%CI,45-70)。
  • 治疗期(≤90天)≥3级不良事件79%,细胞因子释放综合征38%(3级2%),神经系统事件31%(3级5%),≥3级感染7%。
  • 治疗后(≥91天)57例中≥3级不良事件18%,≥3级感染1例。

临床怎么用

  • 作者认为结果支持lisocabtagene maraleucel作为不适合造血干细胞移植的复发/难治性大B细胞淋巴瘤患者的二线治疗。

局限性

  • 白细胞采集集(n=74)中30例死亡,多数死于疾病进展(n=24)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report final analysis results from the PILOT study of lisocabtagene maraleucel (liso-cel) for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Sixty-one adults with R/R LBCL who had received 1 previous line of therapy and met ≥1 hematopoietic stem cell transplantation (HSCT) not intended criterion. Overall response rate (primary end point) was 80%; 54% achieved complete response. After median on-study follow-up of 18.2 months, median duration of response was 23.3 months (95% confidence interval [CI], 6.2 to not reached [NR]). Median progression-free survival (PFS) was 9.0 months (95% CI, 4.2 to NR), median overall survival (OS) was NR (95% CI, 16.3 to NR), and 18-month PFS and OS rates were 43% (95% CI, 30-55) and 59% (95% CI, 45-70), respectively. In the treatment-emergent (TE) period (≤90 days after liso-cel administration), 79% had grade ≥3 adverse events (AEs), 38% had cytokine release syndrome (2% grade 3; no grade 4/5), 31% had neurological events (5% grade 3; no grade 4/5), and 7% had grade ≥3 infections. Of 57 patients in the post-TE period (≥91 days after liso-cel administration), 18% experienced grade ≥3 AEs; 1 patient had grade ≥3 infections. Thirty patients in the leukapheresis set (n = 74) died, mostly of disease progression (n = 24). In this population with high incidence of high-grade B-cell lymphoma, primary-refractory disease, advanced age, and comorbidities, liso-cel demonstrated durable efficacy and a favorable safety profile, consistent with previous reports. These results support liso-cel as second-line therapy for this underserved population of patients with R/R LBCL not intended for HSCT. This trial was registered at www.clinicaltrials.gov as #NCT03483103.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study. Blood Adv. 2025. PMID: 40305658. doi:10.1182/bloodadvances.2024015262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。